MODUCIN-1 (MODUcare for CIN1) is a prospective, single center, open-label, randomized trial that its purpose is to compare MODUCARE versus Wait-and-See Approach for the regression rate of histologically proven low-grade Cervical Intraepithelial Neoplasia (CIN1).
Histologically proven CIN1
Any HPV status (negative, positive: high or low risk)
Any Pap test result
Age 18 - 85 years old
Pregnancy
Low likelihood of patient compliance to treatment protocol and follow-up
Previous operation to the cervix
Previous pelvic malignancy
Aristotle University Of Thessaloniki
Lead sponsor
INPA S.A.
Collaborator